Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | INCA33890 |
| Trade Name | |
| Synonyms | INCA-33890|INCA 33890 |
| Drug Descriptions |
INCA33890 is a bispecific antibody targeting PDCD1 (PD-1) and TGFBR2, which potentially induces cytokine production and inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 2936). |
| DrugClasses | PD-L1/PD-1 antibody 132 TGFBR2 Antibody 3 |
| CAS Registry Number | NA |
| NCIT ID | C201142 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Fluorouracil + INCA33890 + Irinotecan + Leucovorin | Bevacizumab Fluorouracil INCA33890 Irinotecan Leucovorin | 0 | 1 |
| Bevacizumab + Fluorouracil + INCA33890 + Leucovorin + Oxaliplatin | Bevacizumab Fluorouracil INCA33890 Leucovorin Oxaliplatin | 0 | 1 |
| Bevacizumab + INCA33890 | Bevacizumab INCA33890 | 0 | 1 |
| Cetuximab + INCA33890 | Cetuximab INCA33890 | 0 | 1 |
| INCA33890 | INCA33890 | 0 | 1 |
| INCA33890 + INCB161734 | INCA33890 INCB161734 | 0 | 1 |